Replies to post #228290 on Biotech Values

[DewDiligence]

Re: VIR HBV program

From your post:

The company anticipates that two new trials with VIR-2218 will start later this year, including a Phase 2 trial of VIR-2218 in China, in collaboration with Brii Biosciences, and a Phase 2 combination trial of VIR-2218 and pegylated interferon-alpha.

It’s been a long time since I’ve seen a new trial that tests combination therapy with peg-ifn. Such a regimen might make sense in certain emerging markets, but I doubt that it will be an enterprising proposition for the US, EU, or Japan.

p.s. ENTA plans to report phase-1 top-line data in HBV during the current quarter.